Natural Killer (NK) cells, integral to the body’s innate immune system, are gaining attention in the study of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). These cells are known for their ability to detect and respond to abnormal, stressed, or infected cells, and they can also influence inflammation by interacting with other immune cells and releasing signaling molecules. While research is in the early stages, scientists are eager to explore whether NK cells can play a role in addressing the complex processes of chronic inflammation and abnormal protein accumulation observed in these conditions.
Recent studies have begun to shed light on the potential of NK cells in treating Alzheimer’s disease. A Phase I clinical trial conducted in 2025 examined the safety of autologous, non-genetically modified expanded NK cells in 11 patients with Alzheimer’s. Participants received infusions at three-week intervals, and researchers focused on safety while also monitoring cognitive metrics and biomarkers linked to neurodegeneration, neuroinflammation, amyloid, and tau. The trial reported no adverse effects directly tied to the NK cell product and noted preliminary changes in cognitive measures and biomarkers such as pTau181 and GFAP. However, the study’s limited scope means that further, larger trials are necessary to determine any significant clinical benefits of NK cell therapy for Alzheimer’s.
Interest in NK cells extends to Parkinson’s disease as well. Preclinical studies, including one published in 2020 in the Proceedings of the National Academy of Sciences, have demonstrated that NK cells can interact with and degrade alpha-synuclein aggregates in lab and animal models. Additionally, the depletion of NK cells in a mouse model led to increased alpha-synuclein pathology and neuroinflammation, indicating a potential regulatory role for NK cells in Parkinson’s disease. Yet, these findings remain primarily preclinical, and more research is required to establish whether NK cell therapy could be viable in treating Parkinson’s in humans.
The exploration of NK cells in neurological diseases underscores their complex role, with different populations of these cells performing distinct functions depending on the disease type, stage, and tissue environment. Simply increasing the number of NK cells may not yield beneficial outcomes; researchers are investigating which populations, activation states, doses, and treatment schedules might be effective. Important questions remain about the ability of infused NK cells to impact the central nervous system, their duration of activity, potential patient benefits, and whether they can alter the course of neurodegenerative diseases.
While NK cells are recognized for their role in immune surveillance and regulation, their therapeutic potential in neurodegenerative diseases is still under investigation. Early research has piqued interest, particularly in their interaction with neuroinflammation and abnormal protein aggregates like alpha-synuclein. However, the evidence is not yet sufficient to establish NK cell therapy as a treatment for these conditions. Individuals considering cellular therapies are advised to consult healthcare professionals, review scientific evidence, and assess safety and regulatory information. This article is intended for educational purposes and does not offer medical advice or treatment options, as NK cell therapy remains an investigational area in cellular medicine.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.